Two Sigma Investments LP Sells 29,809 Shares of DaVita Inc. (NYSE:DVA)

Two Sigma Investments LP cut its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 94.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,859 shares of the company's stock after selling 29,809 shares during the quarter. Two Sigma Investments LP's holdings in DaVita were worth $278,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Yousif Capital Management LLC grew its position in shares of DaVita by 22.1% during the fourth quarter. Yousif Capital Management LLC now owns 10,362 shares of the company's stock valued at $1,550,000 after purchasing an additional 1,877 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of DaVita by 30.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,224 shares of the company's stock valued at $956,000 after purchasing an additional 1,465 shares in the last quarter. Choreo LLC grew its position in shares of DaVita by 20.1% during the fourth quarter. Choreo LLC now owns 1,706 shares of the company's stock valued at $256,000 after purchasing an additional 285 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in DaVita in the fourth quarter worth about $597,000. Finally, Strategic Financial Concepts LLC purchased a new position in DaVita in the fourth quarter worth about $9,371,000. 90.12% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on DVA shares. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Truist Financial decreased their price objective on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday, May 19th. Cowen reissued a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Barclays raised their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, DaVita presently has an average rating of "Hold" and a consensus price target of $164.50.

DaVita Trading Down 1.0%

Shares of NYSE DVA traded down $1.42 during trading hours on Friday, reaching $135.93. The stock had a trading volume of 826,047 shares, compared to its average volume of 821,548. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The firm has a market cap of $10.26 billion, a price-to-earnings ratio of 12.66, a P/E/G ratio of 1.07 and a beta of 1.11. The business's fifty day moving average price is $141.36 and its two-hundred day moving average price is $151.18. DaVita Inc. has a 52-week low of $131.76 and a 52-week high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. The firm had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. DaVita's quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.26 earnings per share. Analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.